LONDON, Jan 9 (Reuters) - Britain's ReNeuron Group Plc said that trials of its stem-cell therapy for stroke patients had been put on hold by the U.S. Food and Drug Administration (FDA), sending its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback